Wuhan pharmaceutical company developed innovative sedatives

 "The sedative drug that has been stagnating for 30 years in the world is developed and marketed by our local pharmaceutical company in wuhan.com target=_blank >Wuhan. We will bring this innovative drug to the Health Expo." On November 3, Li Jie, chairman of Renfu Pharmaceutical Group, said excitedly. Looking forward to the Health Expo, Wuhan will show the world China's new achievements in medical care, medicine, health, and anti-epidemic.

Wuhan pharmaceutical company developed innovative sedatives

From November 11th to 14th this year, the second World Health Expo will be held in Wuhan International Expo Center. As the earliest listed health company in Hubei Province and Wuhan's largest pharmaceutical R&D, production, and sales company, Renfu Pharmaceutical Group will display a batch of latest research and development results. Among them, the new class 1 drug "remazolam besylate" is eye-catching.

Li Jie introduced that remazolam besylate was formally approved for marketing in July this year. It is used in painless diagnosis and treatment sedation, ICU sedation and local anesthetic sedation. The listing of this drug breaks the field of sedative drugs widely used in clinical practice at home and abroad. In the past 30 years, there has been no market launch of innovative drugs.

Renfu Medicine's remazolam besylate for injection has undergone 10 years of research and development, with an investment of more than 100 million yuan. Initially, 8 countries and regions including the United States and Japan participated in the development of remazolam besylate. With the strong support of Wuhan scientific and technological talents and other resources, Renfu Medicine successfully completed the research and development, and applied for listing earlier than other countries.

This drug is just one of the new drugs developed by Renfu Medicine. At the Health Expo site, Renfu Medicine will also display Alfentanil, which was approved for marketing in March this year, as a narcotic analgesic for general anesthesia induction and maintenance.

In Wuhan, biomedicine and medical device companies are an important pillar industry. It is reported that Wuhan has attracted more than 1,500 biomedical and medical device companies, such as Fortune 500 companies such as Pfizer, Bayer and other large pharmaceutical companies such as Renfu Pharmaceutical Group. The complete upstream and downstream health industry chain allows Renfu Medicine to deploy its own pharmaceutical industry centered on Wuhan, forming a "one-stop" industrial chain of drug research and development center, drug production base, drug distribution and sales center.

The upcoming second World Health Expo will set up 12 specialized halls including anti-epidemic materials hall, medical equipment hall, biochemical medicine hall, and medical science and technology hall. Renfu Medicine is the curator unit of the A4 Biochemical and Pharmaceutical Museum, which will also bring together world-renowned pharmaceutical companies such as Pfizer, AstraZeneca, and Mingde Bio.

Li Jie said that this is a good opportunity for local pharmaceutical companies in Wuhan and world-renowned pharmaceutical companies to demonstrate and grow together on the same stage. In the future, Renfu Pharmaceutical will continue to assist the development and upgrade of Wuhan's health industry, increase investment in scientific research, develop new products such as generic drugs, first generic drugs, and innovative drugs in teams; increase investment in technology and upgrade all product lines. In order to reach the most advanced international quality standards in the shortest time; carry out the development of large drug distribution information systems and smart pharmacies.

Copyright © 2015.All rights reserved. Wuhan Information - 鄂ICP备16009331号热干面

鄂公网安备 42011502000132号